Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 653.00M | 651.60M | 585.40M | 667.48M | 649.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 653.00M | 651.60M | 585.40M | 667.48M | 649.70M |
| Cost of Revenue | 310.20M | 306.20M | 274.80M | 325.56M | 293.20M |
| Gross Profit | 342.80M | 345.40M | 310.60M | 341.91M | 356.50M |
| SG&A Expenses | 204.20M | 205.00M | 193.50M | 204.36M | 199.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 585.00M | 572.00M | 528.50M | 609.55M | 583.70M |
| Operating Income | 68.00M | 79.60M | 56.90M | 57.93M | 66.00M |
| Income Before Tax | -431.10M | 414.00M | 83.40M | -908.92M | 861.60M |
| Income Tax Expenses | -89.20M | 96.20M | 19.40M | -193.12M | 208.40M |
| Earnings from Continuing Operations | -341.90M | 317.80M | 64.00M | -715.80M | 653.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -341.90M | 317.80M | 64.00M | -715.80M | 653.20M |
| EBIT | 68.00M | 79.60M | 56.90M | 57.93M | 66.00M |
| EBITDA | 112.20M | 120.20M | 95.00M | 97.13M | 104.90M |
| EPS Basic | -12.70 | 11.67 | 2.29 | -25.57 | 23.37 |
| Normalized Basic EPS | 1.66 | 1.86 | 1.89 | 1.40 | 1.52 |
| EPS Diluted | -12.70 | 11.67 | 2.29 | -25.57 | 23.34 |
| Normalized Diluted EPS | 1.66 | 1.86 | 1.88 | 1.40 | 1.52 |
| Average Basic Shares Outstanding | 26.92M | 27.23M | 27.94M | 28.00M | 27.95M |
| Average Diluted Shares Outstanding | 26.92M | 27.23M | 27.96M | 28.00M | 27.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |